<info type="DiseaseOrPhenotypicFeature">Growth hormone deficiency</info> growth hormone dose in <info type="DiseaseOrPhenotypicFeature">growth hormone-deficient</info> adults is not associated with <info type="GeneOrGeneProduct">IGF-1</info> gene polymorphisms.

AIMS: Several <info type="SequenceVariant">SNPs</info> and a <info type="SequenceVariant">microsatellite cytosine-adenine repeat promoter polymorphism</info> of the <info type="GeneOrGeneProduct">IGF-1</info> gene have been reported to be associated with circulating <info type="GeneOrGeneProduct">IGF-1</info> serum concentrations. Variance in <info type="GeneOrGeneProduct">IGF-1</info> concentrations due to genetic variations may affect different response to <info type="ChemicalEntity">growth hormone</info> (<info type="GeneOrGeneProduct">GH</info>) treatment, resulting in different individually required <info type="ChemicalEntity">GH</info>-doses in <info type="DiseaseOrPhenotypicFeature">GH-deficient</info> patients. The aim of this study was to test if the <info type="GeneOrGeneProduct">IGF-1</info> gene polymorphisms are associated with the <info type="ChemicalEntity">GH-dose</info> of <info type="DiseaseOrPhenotypicFeature">GH-deficient</info> adults. MATERIALS & METHODS: A total of nine tagging <info type="SequenceVariant">SNPs</info>, five additionally selected <info type="SequenceVariant">SNPs</info> and a <info type="SequenceVariant">cytosine-adenine repeat polymorphism</info> were determined in 133 <info type="OrganismTaxon">German</info> adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority <info type="OrganismTaxon">Caucasian</info>) with <info type="DiseaseOrPhenotypicFeature">GH-deficiency</info> (<info type="DiseaseOrPhenotypicFeature">GHD</info>) of different origin, derived from the prospective <info type="GeneOrGeneProduct">Pfizer International Metabolic Study</info> (KIMS) <info type="GeneOrGeneProduct">Pharmacogenetics Study</info>. Patients received <info type="ChemicalEntity">GH-treatment</info> for 12 months with finished dose-titration of <info type="ChemicalEntity">GH</info> and centralized <info type="GeneOrGeneProduct">IGF-1</info> measurements. <info type="ChemicalEntity">GH-dose</info> after 1 year of treatment, <info type="GeneOrGeneProduct">IGF-1</info> concentrations, <info type="GeneOrGeneProduct">IGF-1</info>-standard deviation score (<info type="GeneOrGeneProduct">SDS</info>), the <info type="GeneOrGeneProduct">IGF-1</info>:<info type="GeneOrGeneProduct">GH</info> ratio and anthropometric data were analyzed by genotype. RESULTS: Except for <info type="SequenceVariant">rs1019731</info>, which showed a significant difference of <info type="GeneOrGeneProduct">IGF-1</info>-<info type="GeneOrGeneProduct">SDS</info> by genotypes (p = 0.02), all polymorphisms showed no associations with the <info type="ChemicalEntity">GH-doses</info>, <info type="GeneOrGeneProduct">IGF-1</info> concentrations, <info type="GeneOrGeneProduct">IGF-1</info>-<info type="GeneOrGeneProduct">SDS</info> and <info type="GeneOrGeneProduct">IGF-1</info>:<info type="GeneOrGeneProduct">GH</info> ratio after adjusting for the confounding variables <info type="GeneOrGeneProduct">gender</info>, <info type="GeneOrGeneProduct">age</info> and <info type="GeneOrGeneProduct">BMI</info>. CONCLUSION: <info type="GeneOrGeneProduct">IGF-1</info> gene polymorphisms were not associated with the responsiveness to exogenous <info type="ChemicalEntity">GH</info> in <info type="DiseaseOrPhenotypicFeature">GHD</info>. Therefore, genetic variations of the <info type="GeneOrGeneProduct">IGF-1</info> gene seem not to be major influencing factors of the <info type="GeneOrGeneProduct">GH-IGF-axis</info> causing variable response to exogenous <info type="ChemicalEntity">GH-treatment</info>.